What's Happening?
Whitney Brunner, administrator of South Dakota's medical cannabis program, informed the legislative Medical Marijuana Oversight Committee that federal authorities have provided minimal information regarding the reclassification of medical marijuana. Despite
the federal government moving medical marijuana from Schedule I to Schedule III in April, states like South Dakota are left with more questions than answers about the broader implications. Schedule I drugs are considered to have no accepted medical use and a high potential for abuse, while Schedule III drugs are recognized for accepted medical uses and a lower potential for abuse. Recreational marijuana remains a Schedule I drug federally, even as 24 states and the District of Columbia permit its use. South Dakota legalized medical marijuana in 2021 through a ballot measure and has since established a regulatory framework, including licensing and testing. Brunner did not clarify whether South Dakota businesses would need to register with the Drug Enforcement Administration (DEA) or what new compliance requirements they might face. However, Kittrick Jeffries, chairman of the Cannabis Industry Association of South Dakota, noted that some businesses are proactively undergoing the DEA inspection process to become licensed.
Why It's Important?
The federal reclassification of medical marijuana to Schedule III is a significant development for the U.S. cannabis industry, particularly for medical cannabis businesses. Historically, these businesses have been unable to claim federal tax deductions for ordinary business expenses due to marijuana's Schedule I status, placing them at a disadvantage compared to other industries. This reclassification is expected to allow medical cannabis businesses to claim such deductions, improving their financial viability. Furthermore, the change should ease banking access for the industry, as financial institutions have largely avoided working with cannabis businesses due to federal illegality, fearing regulatory penalties. The lack of clear guidance from federal authorities, however, creates uncertainty for state-level programs and businesses, potentially hindering a smooth transition and the full realization of these benefits. This situation highlights the ongoing tension between state-level legalization and federal prohibition, even with incremental changes in federal policy.
What's Next?
South Dakota's medical cannabis program is undergoing internal changes, with Brunner reporting an overhaul of its inspection program to address inconsistent enforcement and missed violations. New procedures, training, and a restructured supervisory system have been implemented, along with a formal process for businesses to challenge citations. A proposed rules package is currently under administrative review, aiming to simplify inventory tracking training, reduce security camera footage retention requirements, and restructure the fine system. This package would introduce a 'corrective action plan' for first-offense minor violations instead of immediate fines, potentially easing the burden on businesses. The ongoing federal unresponsiveness means states will likely continue to navigate the implications of rescheduling with limited direct guidance, potentially leading to varied interpretations and implementation challenges across different states. Businesses may continue to proactively seek DEA licensing in anticipation of future requirements.
Beyond the Headlines
The federal government's reclassification of medical marijuana, while a step towards broader acceptance, underscores a deeper regulatory and legal fragmentation within the U.S. This piecemeal approach creates a complex operational environment for cannabis businesses, forcing them to comply with a patchwork of state and evolving federal regulations. The lack of clear federal communication to states like South Dakota highlights a broader challenge in federal-state relations concerning cannabis policy. This ambiguity can lead to increased legal and operational costs for businesses, as they must anticipate and adapt to potential future federal requirements without explicit directives. Moreover, the distinction between medical and recreational marijuana's federal scheduling creates a two-tiered system, perpetuating the federal prohibition on recreational use despite widespread state-level legalization. This situation raises questions about the long-term trajectory of cannabis policy in the U.S. and the potential for a more comprehensive federal framework.
